Three independent discounted-cash-flow-style models value Keros Therapeutics, Inc. Common Stock every trading day. 0 of 3 currently price KROS above its market price.
| Free Cash Flow model | $-573,640.49 |
| Excess Profit model | $-337,562.30 |
| Residual Earnings model | $-2.55 |
| Dividend Discount model | — |
| Piotroski F-Score | 7 / 9 |
| Return on invested capital | +16.8% |
| Net debt / EBITDA | 0.2× |
| Gross margin | +100.0% |
| Revenue CAGR | +129.8% |
| Cash conversion | 1.2× |
| Dividend yield | — |
| Buyback yield | +0.6% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open KROS in StockKitty